These results, together with previous findings that KIR2DL4 forms a regulatory circuit with IFN-γ, suggest complicated cross-talk between different immune checkpoints mediated by cytokines in trastuzumab-treated breast cancer. This evidence concerns the gene KIR2DL4 and breast cancer.